A Phase 1 interventional study of D5-0.9%NS and Routine home oral rehydration in Hemolytic-Uremic Syndrome, sponsored by University of Calgary. Withdrawn at 1 site in Canada. Open to participants aged 6 Months to 18 Years. Per ClinicalTrials.gov, last updated 2020-11-09.
Sponsored by University of Calgary · Phase 1, Interventional, and Treatment
This study will provide feasibility data regarding the conduct of a clinical trail evaluating the use of early aggressive inpatient intravenous rehydration in children with Shiga Toxin producing E. coli infection.
Background: Shiga toxin-producing Escherichia coli (STEC) cause a spectrum of disease, ranging from asymptomatic carriage to bloody diarrhea and the hemolytic uremic syndrome (HUS). HUS is caused by a toxin that destroys red blood cells, consumes platelets and impairs kidney function. HUS results in morbidity and even death in otherwise healthy children. Over the last 30 years however, there has been extremely limited progress in preventing acute and long-term complications in children with STEC infection. However, it is believed that Shiga toxins generate clots or blockages in the kidneys that damage it much the way strokes cause brain damage. There is emerging evidence that if children with STEC infection are recognized early, then the interval between diarrhea onset and the presence of HUS could be exploited to preserve kidney function through the use of intravenous rehydration.
Study Design: The investigators propose to conduct the first randomized clinical trial of volume expansion therapy in children with STEC infection. Employing Alberta's unique province-wide microbiology network and its only two pediatric tertiary care centres, the investigators will conduct a proof of principal feasibility study that evaluates novel technologies to identify STEC infected children and those at risk for HUS.
Objectives: The primary outcome will be process: number of children recruited. Secondary outcomes will include: 1) resources: retention; refusal; compliance; eligibility criteria; questionnaires; data collection tools; and time requirements; 2) management: capacity and impact on clinical services; 3) scientific: utility of point-of-care STEC diagnostics; use of urine biomarkers to identify high risk children, monitoring of kidney injury and response to therapy; and safety.
Significance: This pilot will provide the necessary data to integrate novel technologies into the design and conduct of a multicentre, multinational, clinical trial that will reduce morbidity and mortality from STEC infection.
Exclusion Criteria:
1. Infusion of 40 mL/kg of 0.9% normal saline (NS) IV over 60 minutes 2. 0.9% NS with 5% dextrose at 150% of standard maintenance volume 3. If urine output is \<0.5 ml/kg/hr over a 12-hour period (AKI Stage 2), repeat 20 mL/kg bolus or boluses of 0.9% NS will be infused as long as there are no signs of central volume overload 4. Oral fluids ad lib along with strict input/output documentation 5. Fluids will be restricted if: A) Anuria for 12 hours OR B) Evidence of fluid overload 6. Daily laboratory tests and in-person assessment until inpatient discharge criteria reached: A) 2 - 4 days since symptom onset AND rising platelet count (\>5% increase) documented over 48 hours in a clinically well child B) ≥5 days since symptom onset AND stable platelet count (\<5% decrease) documented over 48 hours in a clinically well child 7. Repeat hematocrit, platelet, renal function 24 and 72-hours post-discharge.
Drug: D5-0.9%NS
1. Following standard emergency department (ED) care \[volume status assessed; dehydration corrected employing oral rehydration in children with mild to moderate dehydration (most common); IV if severe (rarely)\], children are discharged with saline lock IV (routine procedure across Canadian pediatric EDs). 2. Oral fluids (preferably electrolyte maintenance solutions) ad lib following ED discharge 3. Additional health assessments as required 4. Daily blood tests at a local laboratory with results conveyed daily to the site-investigator until outpatient discharge criteria achieved; no in-person assessment given logistics (i.e. distance), impact on family, and mirroring of standard practice A) 2 - 4 days since symptom onset AND rising platelet count (\>5% increase) documented over 48 hours in a clinically well child B) ≥5 days since symptom onset AND stable platelet count (\<5% decrease) documented over 48 hours in a clinically well child
Drug: Routine home oral rehydration
Admission for intravascular volume expansion
Routine oral fluids as is given at home to all children with acute diarrheal disease
Number of children enrolled in the study protocol
The number of children recruited per month per site will be calculated and will be related to the number screened, number eligible, and number consented.
Time frame: at the end of the 24 month study recruiting period
The proportion of children enrolled in each study arm who develop adverse events
For participants enrolled in each study arm we will quantify the proportion that are admitted to Intensive Care Units, the proportion requiring respiratory support (CPAP, BiPAP, endotracheal intubation), hypoxia defined by the administration of supplemental oxygen, and evidence of congestive heart failure defined by blinded independent reviewers.
Time frame: at the end of the 24 month study recruiting period
Retention
The proportion of children who complete the study protocol
Time frame: at the end of the 24 month study recruiting period
Time requirements
We will quantify the number of hours children remain admitted and to which clinical units
Time frame: at the end of the 24 month study recruiting period
Child/family perspectives
7-item likert scales will be employed to evaluate perspectives of parents and participants as appropriate related to study protocols, procedures and participation
Time frame: at the end of the 24 month study recruiting period
compliance/adherence
The proportion of children enrolled in each study arm who comply with the key interventions of the respective study arms
Time frame: at the end of the 24 month study recruiting period
data collection tool performance
Individual data fields will be audited with respect to data quality, reliability, completeness, timeliness of completion
Time frame: at the end of the 24 month study recruiting period
Impact on clinical services
We will qualitatively explore with the department leads at the respective institutions if the study protocol had any impact on clinical care provided either to the admitted patients or to other patients on their services
Time frame: at the end of the 24 month study recruiting period
Cost
We will quantify the costs per child in each study arm
Time frame: at the end of the 24 month study recruiting period
Point-of-Care STEC diagnosis
diagnostic accuracy compared with standard culture
Time frame: at the end of the 24 month study recruiting period
Urine biomarkers
ability to predict progression to AKI and HUS
Time frame: at the end of the 24 month study recruiting period
Point-of-Care STEC diagnosis
turnaround time
Time frame: at the end of the 24 month study recruiting period
Point-of-Care STEC diagnosis
proportion O157 vs other STEC
Time frame: at the end of the 24 month study recruiting period
Plan to share: Undecided
This study is withdrawn, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Calgary